Results 91 to 100 of about 139,988 (355)
Controlling the polycrystallinity of CuO nanorods enables directional reconstruction into rod‐like structures that stabilize Cu(OH)2 and increase Cu+ ratios, while modulating interfacial water dynamics to enhance C─C coupling and boost C2+ product formation in CO2 electroreduction.
Hyeon‐Seok Bang +15 more
wiley +1 more source
Self‐Immolative Activatable Nanoassembly toward Immuno‐Photodynamic Therapy in TME
A quinone methide‐gated, self‐immolative, H2O2‐responsive nano‐photosensitizer (Pyz/PS) is developed for targeted immuno‐photodynamic therapy. Pyz/PS selectively activates within tumor microenvironments, restores photosensitizer activity, generates ROS, and depletes intracellular GSH, enhancing oxidative stress.
Jing Li +10 more
wiley +1 more source
RENAL SAFETY OF PROTON PUMP INHIBITORS
Proton pump inhibitors are a widely used in clinical practice, and are taken by millions of patients around the world for a long time. While proton pump inhibitors are well-tolerated class of drugs, the number of publications has been raised about ...
A. I. Dyadyk, T. E. Kugler
doaj +1 more source
Nonsteroidal anti-inflammatory drugs (NSAIDs) are often coadministered with proton-pump inhibitors (PPIs) to reduce NSAID-induced gastrointestinal (GI) adverse events.
K. Gwee +3 more
semanticscholar +1 more source
A rationally engineered bifunctional photocatalyst is reported, which achieves simultaneous selective oxidation of biomass‐derived 5‐hydroxymethylfurfural (HMF) to 2,5‐diformylfuran (DFF) and efficient H2 evolution. By precisely positioning Au and Co3O4 on Zn3In2S6 nanosheet, dual interfacial electric fields are well constructed to spatially separate ...
Shiqing Li +8 more
wiley +1 more source
Objective: To evaluate serum prolactin and macroprolactin levels in patients on long-term proton pump inhibitors therapy. Method: The cross-sectional study was conducted from January 2018 to November 2019 after approval from the ethics review ...
Muhammad Ashfaq +3 more
doaj +1 more source
Pharmacogenetics of proton pump inhibitors
Proton pump inhibitors (PPI) are currently the most effective class of antisecretory drugs widely used in the treatment of non-ulcer dyspepsia, reflux esophagitis and GERD, peptic ulcer disease and H. pilory infection, as well as NSAID-associated gastric
M. V. Leonova
doaj +1 more source
Bio‐based and (semi‐)synthetic zwitterion‐modified novel materials and fully synthetic next‐generation alternatives show the importance of material design for different biomedical applications. The zwitterionic character affects the physiochemical behavior of the material and deepens the understanding of chemical interaction mechanisms within the ...
Theresa M. Lutz +3 more
wiley +1 more source
Research of the assortment of the proton pump inhibitors on the regional drugs market
Proton pump inhibitors are new most effective remedies for the treatment of gastric ulcer and duodenal ulcer. Analysis results of proton pump inhibitors assortment on the regional market are presented in the article.
O G Ivchenko +4 more
doaj
Safety of proton pump inhibitors
Aim of review. To present modern data on the possible mechanisms of development of side effects of the proton pump inhibitors (PPI). Summary. Proton pump inhibitors is the class of pharmaceuticals that block N+/K+-ATPase of gastric parietal cells.
Ye. A. Losik
doaj +1 more source

